ALK-positive anaplastic large cell lymphoma
MONDO:0017602ALK-positive anaplastic large cell lymphoma (ALK+ ALCL) is a type of ALCL, a rare and aggressive peripheral T-cell non-Hodgkin lymphoma affecting lymph nodes and extranodal sites, which is characterized by the expression of a protein called anaplastic lymphoma kinase (ALK).
Also known as: ALCL, ALK+, ALK+ ALCL, ALK+ anaplastic large cell lymphoma, ALK-positive anaplastic large cell lymphoma, ALKoma, anaplastic large cell lymphoma, ALK-positive
1961 clinical trials for this condition and its sub-types, 22 tagged with ALK-positive anaplastic large cell lymphoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New drug combo shows promise for rare blood cancer in early trial
Disease control CompletedThis study tests adding the drug romidepsin to standard chemotherapy (CHOEP) for young adults (ages 18-65) with a rare type of lymphoma called peripheral T-cell lymphoma. The goal is to see if this combination is safe and effective before patients undergo a stem cell transplant. …
Phase 1/2 • Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
New hope for rare lymphoma: lorlatinib trial targets Drug-Resistant cancers
Disease control CompletedThis phase 2 trial tested the oral drug lorlatinib in 9 people with ALK-positive anaplastic large cell lymphoma whose cancer had returned or stopped responding to previous ALK inhibitors. The main goal was to see how many patients' tumors shrank or disappeared. Researchers also t…
Phase 2 • Sponsor: University of Milano Bicocca • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New cocktail targets tough lymphomas
Disease control CompletedThis early-phase study tested a combination of three drugs (VIP152, venetoclax, and prednisone) in 8 adults with aggressive non-Hodgkin lymphomas that had returned or not responded to prior treatments. The main goals were to check safety and find the best dose, while also measuri…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Your Child's genes: a new clue in fighting a rare cancer?
Knowledge-focused CompletedThis study looks at whether natural variations in immune-related genes affect how well children with a rare type of lymphoma (ALCL) respond to treatment. By analyzing blood samples from 185 patients, researchers hope to find genetic markers linked to longer periods without the di…
Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Knowledge-focused
Last updated Aug 19, 2026 00:00 UTC